Drug Patents owned by Merck

1. List of Emend drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 26 March, 2003

Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

2. List of Zolinza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7456219 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7652069 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2023

(26 days from now)

US7732490 MERCK Methods of treating cancer
Mar, 2023

(26 days from now)

US8067472 MERCK Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Mar, 2023

(26 days from now)

US8101663 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2023

(26 days from now)

US7851509 MERCK Polymorphs of suberoylanilide hydroxamic acid
Feb, 2024

(1 year, 15 days from now)

US7399787 MERCK Methods of treating cancer with HDAC inhibitors
Feb, 2025

(2 years from now)

US8093295 MERCK Formulations of suberoylanilide hydroxamic acid and methods for producing the same
May, 2026

(3 years from now)

US8450372 MERCK Formulations of suberoylanilide hydroxamic acid and methods for producing same
Mar, 2028

(5 years from now)

Drugs and Companies using VORINOSTAT ingredient

Market Authorisation Date: 06 October, 2006

Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in